uniQure (NASDAQ:QURE) Shares Sold by Total Clarity Wealth Management Inc.

Total Clarity Wealth Management Inc. lessened its position in shares of uniQure (NASDAQ:QURE) by 6.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,350 shares of the biotechnology company’s stock after selling 1,100 shares during the period. Total Clarity Wealth Management Inc.’s holdings in uniQure were worth $271,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in QURE. RTW Investments LP acquired a new position in uniQure during the third quarter valued at approximately $49,000. China Universal Asset Management Co. Ltd. raised its position in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc acquired a new position in shares of uniQure during the third quarter worth about $53,000. Quarry LP acquired a new stake in shares of uniQure in the third quarter valued at about $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of uniQure during the 3rd quarter valued at about $69,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Stock Performance

Shares of QURE opened at $15.74 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The business’s fifty day moving average price is $13.90 and its 200 day moving average price is $8.98. The stock has a market capitalization of $767.17 million, a PE ratio of -3.17 and a beta of 0.41.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Equities research analysts forecast that uniQure will post -3.75 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on QURE shares. The Goldman Sachs Group upped their price target on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. Stifel Nicolaus lifted their target price on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Mizuho lifted their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $40.00.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.74% of the stock is owned by company insiders.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.